GeoVax Labs, Inc. (NASDAQ:GOVX) Given Average Rating of “Buy” by Brokerages

Shares of GeoVax Labs, Inc. (NASDAQ:GOVX) have been given a consensus rating of “Buy” by the seven brokerages that are presently covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $14.20.

GOVX has been the topic of several research analyst reports. D. Boral Capital reissued a “buy” rating and set a $18.00 price target on shares of GeoVax Labs in a research note on Friday. HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of GeoVax Labs in a research note on Friday, November 15th. Finally, Alliance Global Partners assumed coverage on GeoVax Labs in a research note on Monday, November 11th. They set a “buy” rating and a $15.00 price objective for the company.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in GeoVax Labs stock. Virtu Financial LLC acquired a new stake in GeoVax Labs, Inc. (NASDAQ:GOVX) in the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 40,210 shares of the company’s stock, valued at approximately $97,000. Virtu Financial LLC owned 0.43% of GeoVax Labs as of its most recent filing with the SEC. 6.09% of the stock is owned by institutional investors.

GeoVax Labs Stock Performance

NASDAQ:GOVX opened at $1.91 on Friday. GeoVax Labs has a 52-week low of $1.09 and a 52-week high of $11.18. The firm’s 50-day moving average is $2.35 and its 200-day moving average is $2.74.

GeoVax Labs (NASDAQ:GOVX) last posted its earnings results on Tuesday, November 12th. The company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($1.29) by $0.38. The company had revenue of $2.79 million for the quarter, compared to the consensus estimate of $1.84 million. During the same quarter last year, the business earned ($4.80) EPS. Sell-side analysts forecast that GeoVax Labs will post -4.49 earnings per share for the current year.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.